Rajiv Agarwal, MD, MS

Steps that need to be taken to address unmet needs and optimize outcomes for patients who have chronic kidney disease and type 2 diabetes.

What to know in terms of the mechanism of action of non-steroidal MRA finerenone compared with other therapies used to treat patients with chronic kidney disease and type 2 diabetes.

Therapies used to help treat patients who have chronic kidney disease and type 2 diabetes.

Considerations for establishing balance for the care of patients with chronic kidney disease among all types of care settings.

What better testing strategies and newer quality measures can do to improve patient referrals to nephrologists for earlier intervention of chronic kidney disease.

A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.

Insight on the unmet needs in management of heart failure, specifically regarding access to therapeutic agents that can alter the course of disease.

Strategies that can help clinicians establish and work toward goals when treating patients with chronic kidney disease to help control disease and prevent progression.

A panel of clinicians explain why action is needed to help prevent the risk of progression of chronic kidney disease.

Rajiv Agarwal, MD, MS, reflects on pooled data from the EMPEROR-Reduced and EMPEROR-Preserved trials.

An overview of and results from the EMPEROR-Preserved trial, which tested the effects of empagliflozin in patients with HFpEF.

Financial and clinical concerns surrounding the burden of chronic kidney disease progression, as well as social determinants that factor into managing the condition in the community.

Strategies to help clinicians talk with patients about chronic kidney disease staging and what to expect in terms of prognosis.

Rajiv Agarwal, MD, MS, considers the practical implications of the FIDELITY pooled analysis and how it may impact clinical practice.

Drs Rajiv Agarwal and Eugene Wright Jr. highlight risk factors associated with chronic kidney disease and react to concerns surrounding the assessment and treatment of patients.

A review of results from the FIDELITY pooled analysis analyzing finerenone’s impact on cardiorenal morbidity and mortality in patients with type 2 diabetes and CKD.

An overview of the FIDELITY analysis, which pooled data from the FIGARO-DKD and FIDELIO-DKD trials in patients with type 2 diabetes and CKD.

Rajiv Agarwal, MD, MS, shares expert insight on the results of FIGARO-DKD with respect to the trial’s primary and secondary end points.

An overview of the FIGARO-DKD trial, which evaluated cardiovascular and renal outcomes in patients with type 2 diabetes and CKD treated with finerenone.